RegulationPriority Review (United States), Breakthrough Therapy (United States), Accelerated Approval (United States), Orphan Drug (United States), Orphan Drug (European Union), Orphan Drug (Japan), Orphan Drug (South Korea), Priority Review (Australia), Fast Track (United States)

Structure/Sequence

Molecular FormulaC20H19Cl2F2N5O3

InChIKeyHGCOOPLEWPBLOY-PFEQFJNWSA-N

CAS Registry2119669-71-3

Clinical Trials associated with Asciminib Hydrochloride

NCT07354074

/ Not yet recruitingPhase 2

A Phase II, Multicenter, Open-label, Single Arm Study to Evaluate the Safety and Efficacy of Asciminib in Pediatric Participants Newly Diagnosed or Previously Treated With Philadelphia Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) With or Without Known T315I Mutation

The aim of this study is to support development of asciminib in the pediatric population (1 to < 18 years) with Ph+ CML-CP. The study will evaluate the efficacy and safety of asciminib in pediatric formulation (weigh-based dose, fed state) or adult formulation (fasted) in newly diagnosed and resistant or intolerant Ph+ CML-CP with or without T315I mutation.

Start Date04 May 2026

Sponsor / Collaborator

Novartis Pharmaceuticals Canada, Inc.

NCT07040982

/ Not yet recruitingPhase 1IIT

Pilot Study of Asciminib as a Maintenance Treatment Post Cellular Therapies in Adults With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

This phase I trial tests the safety, side effects and best dose of asciminib as maintenance treatment for adults with Philadelphia chromosome positive acute lymphoblastic leukemia (ALL) who have undergone cellular therapies such as hematopoietic stem cell transplantation (HSCT) or chimeric antigen receptor (CAR) T cell therapy. Maintenance treatment is given to help keep cancer from coming back after it has disappeared following initial therapy. Asciminib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving asciminib may be safe and tolerable as maintenance treatment for adult patients with Philadelphia chromosome positive ALL who have undergone cellular therapies.

Start Date01 May 2026

Sponsor / Collaborator

City of Hope National Medical Center

[+1]

NCT07039760

/ Not yet recruitingEarly Phase 1IIT

An Early Phase 1 Study of Asciminib With or Without Sildenafil for Brain Tumors

Dissemination of medulloblastoma is an independent risk factor of poor prognosis. Dissemination of medulloblastoma at recurrence is nearly universally fatal. ABL1 and 2 have been recently found to mediate the dissemination of medulloblastoma. Genetically inactivating ABL1 and 2 resulted in decreased leptomeningeal medulloblastoma and improved overall survival (OS) in rodent models. Asciminib is an FDA approved for the treatment of chronic myeloid leukemia and is well tolerated, likely due to its specificity for ABL1 and ABL2. Asciminib is a P-glycoprotein (P-gp) substrate and thus may be susceptible to being pumped out of tumor cells and brain endothelial cells. It is unclear if asciminib can enter the central nervous system (CNS) and brain tumors in adequate concentration to have anti-tumor effects.

Start Date30 Apr 2026

Sponsor / Collaborator

Washington University School of Medicine

100 Clinical Results associated with Asciminib Hydrochloride

100 Translational Medicine associated with Asciminib Hydrochloride

100 Patents (Medical) associated with Asciminib Hydrochloride

336

Literatures (Medical) associated with Asciminib Hydrochloride

01 Apr 2026·Hematology Transfusion and Cell Therapy

Is asciminib an effective tyrosine kinase inhibitor for chronic myeloid leukemia patients with tyrosine kinase inhibitor resistance?

Review

Author: Alanazi, Majed A ; Jackson, Denise E ; Omar, Musab Ma

Asciminib represents a significant advancement in the treatment of chronic myeloid leukemia, establishing a novel therapeutic paradigm by specifically targeting the ABL1 myristoyl pocket, a mechanism distinct from that of conventional adenosine triphosphate-competitive inhibitors. Such a selective inhibitor offers an alternative treatment strategy for patients with chronic myeloid leukemia who have developed resistance to previous tyrosine kinase inhibitor therapies. Although asciminib demonstrates a superior safety profile, primarily characterized by a reduction in cardiovascular adverse events associated with prior tyrosine kinase inhibitors, its clinical significance extends further. The effectiveness of asciminib, combined with its capacity to overcome resistance through combination strategies with adenosine triphosphate-binding site tyrosine kinase inhibitors, establishes it as a focal point in emerging chronic myeloid leukemia treatment approaches. It remains essential to continue research and clinical trials to enhance the therapeutic efficacy of asciminib and manage its associated side effects.

04 Mar 2026·Expert Review of Hematology

Addressing unmet needs in chronic myeloid leukemia in chronic phase treated with two or more tyrosine kinase inhibitors: insights from literature and Indian clinical practice

Review

Author: Saini, Kuldeep ; Jain, Rishi ; Gundeti, Sadashivudu ; Sharma, Lalit Mohan ; Bhattacharya, Jina ; Shetty, Disha ; Bagal, Bhausaheb ; Baul, Shuvra Neel ; Kumar, Sujeet ; Sharma, Vishnu ; Nair, Velu ; Malhotra, Hemant ; Nag, Arijit ; Verma, Shailendra Prasad ; Yadav, Sanjeev ; Jena, Rabindra Kumar

INTRODUCTION:

Chronic myeloid leukemia (CML) is a myeloproliferative disorder, usually diagnosed in its chronic phase (CP), often requiring life-long therapy. Despite the effectiveness of targeted therapy with tyrosine kinase inhibitors (TKIs), resistance or intolerance may occur, requiring a switch. The probability of achieving guideline-recommended cytogenetic and molecular responses declines from first (1 L) to second (2 L) and subsequent lines. About half of the patients receiving third line TKI treatment exhibit resistance or intolerance to prior TKIs. Post-2 L, patients experience non-durable responses, persistent adverse events, and a decreased quality of life.

AREAS COVERED:

This narrative review is based on targeted literature search in Medline via PubMed and expert clinical input from Indian hematologists to cover unmet needs of patients with CP-CML post-2 L of TKI therapy. We present an overview of the available clinical data, outline the challenges associated with treatment resistance and intolerance, identify gaps in patient management, and discuss personalized treatment approaches that could bridge these gaps and improve patient outcomes post-2 L.

EXPERT OPINION:

Management of CP-CML beyond 2 L remains a significant clinical challenge due to resistance, intolerance, and suboptimal long-term responses with currently available TKIs. Integrating newer agents like asciminib or ponatinib, can help overcome resistance and improve patient outcomes.

04 Mar 2026·Expert Review of Hematology

Specifically targeting the ABL myristoyl pocket: STAMP inhibitors for chronic myeloid leukemia

Review

Author: Kimura, Shinya ; Ureshino, Hiroshi

INTRODUCTION:

Chronic myeloid leukemia (CML) has been transformed by ATP-competitive BCR:ABL1 tyrosine kinase inhibitors (TKIs); however, resistance, intolerance, and long-term toxicity remain clinically relevant challenges, particularly in patients requiring prolonged therapy or multiple treatment lines. Asciminib, the first-in-class Specifically Targeting the ABL Myristoyl Pocket (STAMP) inhibitor, represents a paradigm shift by restoring physiologic ABL1 autoinhibition through allosteric binding.

AREAS COVERED:

This Special Report reviews the mechanistic basis, preclinical development, and clinical evidence supporting asciminib in CML. We summarize key data from pivotal trials, including ASCEMBL and ASC4FIRST, as well as emerging real-world studies, focusing on molecular response depth, safety, resistance mechanisms, and patient selection. Particular attention is paid to how STAMP inhibition differs from ATP-competitive TKIs in terms of selectivity, toxicity profile, and resistance patterns, and how asciminib can be positioned relative to ponatinib in later-line settings.

EXPERT OPINION:

Asciminib has established itself as an effective and generally well-tolerated option for patients with TKI-resistant or -intolerant CML and is poised to expand into earlier lines of therapy. Its ability to induce rapid and deep molecular responses with reduced off-target toxicity may have important implications for long-term disease control and future treatment-free remission (TFR) strategies. Ongoing studies will clarify its optimal sequencing, combination potential, and role in facilitating durable TFR.

157

News (Medical) associated with Asciminib Hydrochloride

28 Mar 2026

·endpoints.news

A week of bolt-on deals; Wave crashes on obesity data; Sanofi partners with TCE startup; and more

Welcome back to Endpoints Weekly! Our team tracked a handful of deals announced this week as the first quarter comes to a close. Check below for a summary of those moves, including Merck’s $6.7 billion deal to acquire Terns. Meanwhile, Sanofi unveiled a new partnership with a California startup focused on T cell engagers. Our reporters also covered two FDA approvals for rare disease treatments and a disappointing readout for Wave’s obesity candidate. — Nicole DeFeudis 💰A triumvirate of large pharma companies pulled off acquisitions this week, apparently treating the end of the first quarter as a self-imposed deadline. The biggest comes from Merck, which scooped up Terns Pharmaceuticals off the public market for $6.7 billion — $53 per share, a 31% premium to Terns’ 60-day average stock price. The centerpiece of the Terns deal is a drug designed to treat chronic myeloid leukemia, a slow-progressing blood cancer. Last December, Terns outlined data for the drug that justified its pivot away from obesity. Merck was evidently impressed: TERN-701 will likely compete with Novartis’ Scemblix, a newly minted blockbuster, should it win approval. Terns had planned to kick off a pivotal study later this year or in early 2027. Novartis also got in on the action, buying out immunology biotech Excellergy for up to $2 billion . It’s a quick exit for a company that only debuted with a $70 million Series A in October . The focus on this deal is Excellergy’s “effector cell response inhibitors,” designed to interfere with overactive immune responses related to immunoglobulin E, or IgE. Excellergy has said its lead drug could have use in food allergy, chronic hives and asthma. Gilead rounds out this week’s deal flurry with a deal for Ouro Medicines, which is developing T cell engagers for immunologic diseases. Gilead will pay about $1.68 billion upfront , while roping in longtime partner Galapagos to conduct early work on the lead drug. That program, called gamgertamig, is a bispecific targeting BCMA and CD3. 🌊Trying to beat GLP-1s in obesity is a tough road. Wave Life Sciences underlined that reality this week when its obesity candidate yielded weight loss of just 1% more than placebo in an early-stage study. Patients received a single 240 mg dose of WVE-007, a small interfering RNA drug. The FDA’s approvability bar for obesity meds has been set by the FDA at 5%. Wave’s stock price fell nearly 50% in response. The biotech has argued that its drug prioritizes fat loss and retains lean mass. That thesis remained relatively intact after the readout. There was a placebo-adjusted reduction in visceral fat of 14%, which just grazed significance at a p-value below 0.05. At the same dose level, total fat was reduced by 5%, lean mass increased 2% and patients’ average waist circumference fell by 3%, all on a placebo-adjusted basis. Executives still see a path forward. The second part of the study, functioning as a Phase 2, will start by mid-year. Data could come this year or next. The company is also planning to study WVE-007 as an add-on to a GLP-1 drug, and in the post-GLP-1 maintenance setting, this year. 🤝Sanofi is back in on T cell engagers. After a couple years of fluctuating interest in the space, the French pharma giant is teaming up with a California startup in a licensing deal worth $180 million in upfront and near-term payments. The pact focuses on KT501, a trispecific TCE that goes after the well-known targets of CD19, BCMA and CD3. Kali CEO Weihao Xu told Endpoints that the deal was inked in December, but the partners waited until KT501 was in the clinic to announce it. Kali said last week that it began dosing the first cohort of adults with rheumatoid arthritis. The partnership suggests Sanofi is recommitting to TCEs. The company had made a $1 billion bet on TCEs with the purchase of Amunix in 2021, only to then divest those assets to Vir Biotechnology in 2024. Sanofi has dropped other TCEs along the way, including an anti-GPC3 nanobody-based candidate. The Sanofi-partnered asset isn’t all Kali has in the works — it’s just one of multiple medicines the startup hopes to bring into the clinic, including two more that are expected to enter human testing this year. Read more here from Kyle. ✅The FDA approved two rare disease treatments this week, bucking a recent trend of rejections in the space. First came a greenlight for Denali Therapeutics’ Avlayah in Hunter syndrome . The drug became the first to win accelerated approval using heparan sulfate as a surrogate biomarker, a path that eluded two rivals pursuing the same strategy: Ultragenyx and Regenxbio. Both are developing gene therapies for rare diseases under the same genetic umbrella. Then, the FDA’s biologics division approved a gene therapy from Rocket Pharmaceuticals for an ultra-rare immune disease. It’ll be sold as Kresladi and is approved to treat leukocyte adhesion deficiency-I (LAD-I), where patients face serious and potentially deadly bacterial and fungal infections. The nod comes after the FDA rejected the therapy in 2024, leading to layoffs and pipeline cuts at Rocket. ✉️In a warning letter released this week, the FDA raised concerns with California-based ImmunityBio for a TV advertisement and podcast that it said gave the “misleading impression” that Anktiva, the company’s treatment for a type of bladder cancer, can cure or prevent all cancers. The ad and podcast featured billionaire entrepreneur and ImmunityBio founder Patrick Soon-Shiong. In a separate warning letter for a Daman, India-based drug manufacturing facility, the agency made the rare move of posting photographs of dilapidated buildings. The photographs are the latest sign that FDA Commissioner Marty Makary is taking a tougher stance on foreign drug manufacturers. DON’T MISS:

AcquisitionLicense out/inClinical ResultDrug Approval

26 Mar 2026

·www.biopharmadive.com

Merck’s deal for Terns sparks debate over a possible biotech bidding war

Merck & Co.s $6.7 billion bid for Terns Pharmaceuticals took Wall Street by surprise, both because of its timing and the lower-than-anticipated price being paid for a much-heralded treatment that could reshape treatment of chronic myeloid leukemia.Terns drug, called TERN-701, is a type of targeted, oral treatment thats shown early potential to challenge marketed therapies, like Novartis Scemblix, in the treatment of CML. Yet Wall Street analysts have forecast peak annual sales estimates that effectively surpass the net $5.7 billion Merck is paying, when accounting for Terns cash reserves.The 6% purchase premium, among the lowest paid for a publicly traded drugmaker since at least 2018, according to BioPharma Dive data, also added to a sense by some analysts and investors that rival companies may swoop in and top Mercks offer.Moreover, investors dissatisfied with the deal terms could refuse to tender their shares because they view the Merck offer as undervaluing the company.In our assessment, this deal price vastly underestimates the potential for TERN-701, wrote Leerink Partners analyst Andrew Berens, who covers Terns, in a note to clients. A different buyer paying a reasonable multiple of 1.5 to two times peak forecasted sales would represent a meaningful premium to the current bid, he wrote.Terns was formed as a cross-border company aiming to bring innovative medicines to Chinaand initially focused on a common liver disorder called metabolic dysfunction-associated steatohepatitis. The company licensed treatments from Eli Lilly and raised $128 million in an initial public offering in 2021 to support development. Shares premiered at $17 apiece.Terns work in MASH, and then later, obesity, was eventually sidelined, sinking shares as low as less than $2 apiece at one point and under $3 as recently as a year ago. In the meantime, though, it had another therapy, licensed from Chinas Hansoh Pharmaceutical in 2020, that was progressing against CML. That therapy, now known as TERN-701, moved to the forefront as Terns other research struggled and has been the source of a stock revival.The therapys potential was showcased at the American Society of Hematology meeting in December. Data Terns disclosed from an early-stage trial showed a majority of people whose chronic myeloid leukemia had progressed on other similar drugs saw a major molecular response, or a vast reduction in the number of diseased blood cells, after being treated with TERN-701. Analysts were so impressed by the findings they began suggesting Terns drug upend care for CML.Terns shares rocketed to more than $47 apiece following the meeting and have steadily climbed in early 2026. The companys stock price closed at $50 on Tuesday, the day before Merck announced that Terns had accepted a $53-per-share bid.On a conference call with analysts Wednesday, Merck CFO Caroline Litchfield said the deals terms capture the value of TERN-701s sales potential in the U.S. and assume no pricing restrictions from Medicare as well as market exclusivity that extends into the 2040s.To some analysts, that price represents a fair deal. Given Terns long-depressed stock price, the deal represents an excellent outcome for [Terns] shareholders, Mizuho Securities analyst Graig Suvannavejh wrote in a note to clients.Others are convinced Terns is being undervalued. Berens, of Leerink, projects that if TERN-701 is approved, itll surpass $1 billion in annual sales by 2032 and peak at $6.2 billion yearly in 2040. Most people with CML survive 10 years or more following their diagnosis and can expect to have a normal lifespan, making it likely that a tolerable drug that keeps the disease in check will be a big seller. Terns drug, then, should be able to generate multi-blockbuster revenue, especially if it becomes the treatment standard for newly diagnosed patients, Berens wrote.For Merck, those ambitious projections could help it offset the revenue decline expected when its biggest seller, Keytruda, loses patent protection. Merck is eyeing $70 billion in annual sales next decade, and has looked to a combination of acquisitions and in-house research progress to reach that target.The price it negotiated for Terns represents shrewd decision-making by Mercks business development team, RBC Capital Markets Trung Huynh wrote, adding that the absence of non-guaranteed, success-based payouts suggests Merck bested other competitors with a winning bid.Many investors are criticizing rival large drugmakers for being asleep at the wheel allowing such a valuable asset to be acquired at a discount, Hyunh wrote. Yet he and others suggested companies like AbbVie or Bristol Myers Squibb might jump in with a competing offer.We believe any large biopharma with an interest in establishing or building its presence in oncology would be interested,Suvannavejh wrote. '

25 Mar 2026

·www.fiercebiotech.com

Merck, girding for Keytruda cliff, flies toward promising CML asset with $6.7B Terns acquisition

The crown jewel of the acquisition is an oral treatment candidate for patients with chronic myeloid leukemia.\n Merck and Terns Pharmaceuticals have agreed to a $6.7 billion all-cash buyout that delivers a prized leukemia asset to the New Jersey Big Pharma.The crown jewel of the deal is TERN-701, an oral treatment that demonstrated encouraging efficacy and safety signals in a recent trial while also offering greater convenience for patients with chronic myeloid leukemia (CML), a rare cancer of the blood and bone marrow caused by a genetic mutation.Merck will acquire Terns for $53 a share, a 6% premium over Tuesday’s closing price, according to a March 25 release. The deal values the biotech at $5.7 billion when factoring in its $1 billion in cash holdings.A note from William Blair analysts said the deal undervalues TERN-701, which the team believes is poised to disrupt the CML treatment paradigm and challenge Novartis’ Scemblix franchise. Meantime, analysts at Mizuho say the deal value may leave room for another bidder for the CML asset. The agreement, expected to close in the second quarter of this year, will help Merck replenish its oncology pipeline as Keytruda approaches its loss of exclusivity in 2028.TERN-701 is a novel oral allosteric BCR::ABL tyrosine kinase inhibitor (TKI) currently being evaluated in a phase 1/2 trial in patients with Philadelphia chromosome-positive (Ph+) chronic-phase CML who were previously treated with one TKI and experienced treatment failure. In March 2024, TERN-701 received orphan drug designation from the FDA.In a presentation at the American Society of Hematology late last year, TERN-701 reduced the number of diseased white blood cells in patients’ bloodstreams. Although the study was primarily designed to assess safety, Terns described the results as “unprecedented” among CML treatments.TERN-701 has shown promising rates of major molecular response and deep molecular response by week 24, including in patients with high disease burden who had received multiple prior lines of therapy, according to the biotech. Most treatment-emergent adverse events recorded in the study were low grade, with a low incidence of severe adverse events and discontinuations. No meaningful changes in blood pressure were observed, and rates of lipase elevation were low.Terns is preparing to launch late-stage trials toward the end of the year or in early 2027. According to the American Cancer Society, CML accounts for 15% of all new leukemia cases, with about 9,650 people expected to be diagnosed this year.The data prompted bullish reactions from analysts, who noted that Novartis recently raised its peak global sales guidance for Scemblix from $3 billion to $4 billion. First approved for third-line treatment, Scemblix has since been cleared by the FDA for patients with newly diagnosed Ph+ CML. A note from BMO Capital Markets predicts that TERN-701 could achieve unadjusted peak sales of more than $4 billion.The deal is a boost for Terns, which abandoned its oral GLP-1 obesity candidate last year after a phase 2 trial fell short of expectations and showed signs of liver injury. While the company initially planned to seek a partner to advance the asset, the data ultimately ended its development.Still, investor sentiment in the wake of the announcement “appears mixed,” Leerink analysts wrote to clients Wednesday. Some Terns investors were happy to enjoy the stock’s quick appreciation and buyout, while others thought the company left value on the table by selling for the price it did. Merck\'s Keytruda LOE positioning Merck, which remained pharma\'s top R&D spender in 2025, has been on an acquisition streak. Last July, it acquired Verona for $10 billion to bolster its respiratory portfolio with potential chronic obstructive pulmonary disease blockbuster Ohtuvayre. In November, Merck spent $9.2 billion on Cidara Therapeutics, targeting its lead influenza antiviral, which had previously been abandoned by Johnson & Johnson in 2024.As part of last month’s full-year earnings presentation, Merck CEO Robert Davis said the Cidara and Verona acquisitions will help drive the company toward more than $70 billion in annual revenue opportunities by the “mid-2030s.” Merck reported $65 billion in revenue in 2025, up 1% from 2024, with Keytruda accounting for $31.7 billion in sales.Wednesday, Davis said in a statement that the Terns acquisition allows Merck to add a potential best-in-class candidate for patients with CML as the company continues “to look for opportunities to broaden our portfolio into other therapeutic areas.”

Clinical ResultAcquisitionDrug ApprovalOrphan DrugASH

100 Deals associated with Asciminib Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D11403 D11404	-	-	DB12597

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase with the T315I mutation	United States	Novartis Pharmaceuticals Corp.	29 Oct 2024
Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase	Australia	Novartis Pharmaceuticals Australia Pty Ltd.	15 Jul 2022
Chronic Myelogenous Leukemia	Japan	Novartis Pharmaceuticals KK	28 Mar 2022
Philadelphia chromosome positive chronic myelogenous leukemia	United States	Novartis Pharmaceuticals Corp.	29 Oct 2021

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Philadelphia positive acute lymphocytic leukaemia	Phase 3	United States	Novartis Pharma AG	30 Aug 2022
Philadelphia positive acute lymphocytic leukaemia	Phase 3	Japan	Novartis Pharma AG	30 Aug 2022
Philadelphia positive acute lymphocytic leukaemia	Phase 3	Argentina	Novartis Pharma AG	30 Aug 2022
Philadelphia positive acute lymphocytic leukaemia	Phase 3	Austria	Novartis Pharma AG	30 Aug 2022
Philadelphia positive acute lymphocytic leukaemia	Phase 3	Brazil	Novartis Pharma AG	30 Aug 2022
Philadelphia positive acute lymphocytic leukaemia	Phase 3	Bulgaria	Novartis Pharma AG	30 Aug 2022
Philadelphia positive acute lymphocytic leukaemia	Phase 3	Canada	Novartis Pharma AG	30 Aug 2022
Philadelphia positive acute lymphocytic leukaemia	Phase 3	Czechia	Novartis Pharma AG	30 Aug 2022
Philadelphia positive acute lymphocytic leukaemia	Phase 3	Denmark	Novartis Pharma AG	30 Aug 2022
Philadelphia positive acute lymphocytic leukaemia	Phase 3	France	Novartis Pharma AG	30 Aug 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


AACR2026	Not Applicable	Chronic Myelogenous Leukemia	291	Ponatinib	qxrkyfegtw(tkdzvzemga) = jtzpktrvgd yzcsbqryco (iqymcwwwzz )	Positive	21 Apr 2026
				Bosutinib	cjpljaikxd(dkdtijemtr) = gvpmwpoxxc tpttpzhzxf (qgbgdfhksv ) View more
NCT04216563 (CTgov)	Phase 2	Chronic phase chronic myeloid leukemia \| Residual Neoplasm \| Philadelphia chromosome positive chronic myelogenous leukemia	7	Asciminib	jgmrnwuljf = avfeilwdui cstsgrwjws (rxpvxtfviw, hlndxaicfx - jygzfyuvar) View more	-	09 Jan 2026
NCT05384587 (ASC2ESCALATE, ASH2025)	Phase 2	Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase First line	95	Asciminib (ASC)	qhncjkzvny(ywhkrkiaqm) = vfjwaoiqxl eqlrthckhg (rkesshtseu ) View more	Positive	06 Dec 2025
ASH2025	Not Applicable	Chronic Myelogenous Leukemia	68	Asciminib	isbnlcphje(eysjujjvzd) = dlhzrpetvc lbectauwty (jcfbbneitd ) View more	Negative	06 Dec 2025
				Asciminib (Somatic mutations (SM) presence)	skgrkibefp(cvywkygawp) = yfmawdbhbv gydtmbpslo (vpjoevylqs ) View more
ASH2025	Not Applicable	Chronic phase chronic myeloid leukemia Second line	392	Asciminib	sxeinlcktx(hlswxlgarn) = ykabbdfexq gtayawazpx (otdxusifey ) View more	Positive	06 Dec 2025
				ATP-competitive TKIs (dasatinib, nilotinib, bosutinib, imatinib)	sxeinlcktx(hlswxlgarn) = ngqhnzayxl gtayawazpx (otdxusifey ) View more
NCT04971226 (ASC4FIRST, ASH2025)	Phase 3	Chronic Myelogenous Leukemia	415	Asciminib	xnmnhkhisn(dynaaclfhl) = itrysowqik iuxdhhbcrm (vagofzekni ) View more	Positive	06 Dec 2025
				2G TKIs (dasatinib, nilotinib, bosutinib)	xnmnhkhisn(dynaaclfhl) = zjgfejgjoo iuxdhhbcrm (vagofzekni ) View more
ASH2025	Not Applicable	Philadelphia positive acute lymphocytic leukaemia	3,002	Asciminib-based therapy	bmhdugeftb(thbzksygwk) = 32.5% of pts had a clinical event with a diagnosis for pleural effusion, 17.0% for an arterial occlusive event (myocardial infarction, ischemic cardiovascular event, angina), and 70% for a gastrointestinal event (nausea, vomiting, constipation, diarrhea) xkoovnrzap (rulwdyjqkv ) View more	Positive	06 Dec 2025
NCT05384587 (ASC2ESCALATE, ASH2025)	Phase 2	Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase	101	Asciminib (ASC) 80 mg QD	rzqmvxmgen(maxawcmjgu) = orjgcnnpjz cbmvwptcnw (qinwfrlzho ) View more	Positive	06 Dec 2025
NCT04971226 (ASC4FIRST, ASH2025)	Phase 4	Chronic phase chronic myeloid leukemia ASXL1 mutation	341	Asciminib	moknxxhglm(rxwlabthcs) = yyxrgcccbg altddfphjn (eqrjgturep ) View more	Positive	06 Dec 2025
				Investigator-selected tyrosine kinase inhibitors (IS-TKI)	moknxxhglm(rxwlabthcs) = griucuaozw altddfphjn (eqrjgturep ) View more
NCT04971226 (ASC4FIRST, ASH2025)	Phase 3	Chronic phase chronic myeloid leukemia	501	Asciminib	jnuhcqsxjc(ddcmmlnwey): OR = 2.58 (95.0% CI, 1.67 - 3.98) View more	Positive	06 Dec 2025
				Dasatinib

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis